Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer

Cancer Discovery

Volumn 6, Issue 2, 2016, Pages 147-153

  Russo, Mariangela ^a,b,c   Siravegna, Giulia ^a,b   Blaszkowsky, Lawrence S ^d,e   Corti, Giorgio ^a   Crisafulli, Giovanni ^a   Ahronian, Leanne G ^d,e   Mussolin, Benedetta ^a   Kwak, Eunice L ^d,e   Buscarino, Michela ^a   Lazzari, Luca ^a   Valtorta, Emanuele ^f   Truini, Mauro ^f   Jessop, Nicholas A ^g   Robinson, Hayley E ^g   Hong, Theodore S ^d,g   Mino Kenudson, Mari ^g   Di Nicolantonio, Federica ^a,b   Thabet, Ashraf ^g   Sartore Bianchi, Andrea ^f   Siena, Salvatore ^f   Iafrate, John ^g   Bardelli, Alberto ^a,b   Corcoran, Ryan B ^d,e   more..

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; CETUXIMAB; CIRCULATING TUMOR DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PANITUMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; DNA; KRAS PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN P21;

ARTICLE; BLOOD SAMPLING; CANCER RESISTANCE; CAPILLARY ELECTROPHORESIS; CELL HETEROGENEITY; CELL PROLIFERATION ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; ONCOGENE; PROTEIN EXPRESSION; RADIOGRAPHY; TUMOR BIOPSY; WESTERN BLOTTING; BLOOD; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; LIVER NEOPLASMS; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE 1; MOLECULAR TARGETED THERAPY; MUTATION; PRECISION MEDICINE; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84957063275     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1283     Document Type: Article

References (22)

1. Garraway LA, Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012; 2: 214-26.
2. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225–33.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
4. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015; 27: 15-26.
5. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883–92.
6. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra24.
7. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015; 5: 713-22.
8. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
9. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
10. Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358-67.
11. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
12. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
13. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
14. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015; 526: 263-7.
15. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 795-801.
16. Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015; 21: 2157-66.
17. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008; 68: 5524-8.
18. Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res 2015; 21: 1935-43.
19. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014; 6: 224ra26.
20. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
21. Van Cutsem E, Atreya C, André T, Bendell J, Schellens J, Gordon M, et al. LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Oncol 2015; 26: iv119.
22. Whitehead RH, Macrae FA, St John DJ, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer I 1985; 74: 759-65.